D Travis Gallagher
Overview
Explore the profile of D Travis Gallagher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Motabar D, Kim E, Li J, Zhao Z, Mouchahoir T, Gallagher D, et al.
Nat Chem Biol
. 2024 Dec;
21(2):291-299.
PMID: 39623022
Protein function relies on sequence, folding and post-translational modification and molecular measurements are commonly used to reveal these structural features. Here, we report an alternative approach that represents these molecular...
2.
Bergonzo C, Hoopes J, Kelman Z, Gallagher D
J Biomol Struct Dyn
. 2023 Oct;
42(22):12571-12579.
PMID: 37897185
The crystallizable fragment (Fc) domain of immunoglobulin subclass IgG1 antibodies is engineered for a wide variety of pharmaceutical applications. Two important structural variables in Fc constructs are the hinge region...
3.
Choy C, Chen J, Li J, Gallagher D, Lu J, Wu D, et al.
Nat Commun
. 2023 Oct;
14(1):6725.
PMID: 37872153
The resolution of SARS-CoV-2 replication hinges on cell-mediated immunity, wherein CD8 T cells play a vital role. Nonetheless, the characterization of the specificity and TCR composition of CD8 T cells...
4.
Gallagher D, Oganesyan N, Lees A
Acta Crystallogr F Struct Biol Commun
. 2023 Mar;
79(Pt 4):82-86.
PMID: 36995122
CRM is a genetically detoxified mutant of diphtheria toxin (DT) that is widely used as a carrier protein in conjugate vaccines. Protective immune responses to several bacterial diseases are obtained...
5.
Ruan B, He Y, Chen Y, Choi E, Chen Y, Motabar D, et al.
Nat Commun
. 2023 Jan;
14(1):431.
PMID: 36702827
To better understand how amino acid sequence encodes protein structure, we engineered mutational pathways that connect three common folds (3α, β-grasp, and α/β-plait). The structures of proteins at high sequence-identity...
6.
Solomon T, He Y, Sari N, Chen Y, Gallagher D, Bryan P, et al.
Proc Natl Acad Sci U S A
. 2023 Jan;
120(4):e2215418120.
PMID: 36669114
Naturally occurring metamorphic proteins have the ability to interconvert from one folded state to another through either a limited set of mutations or by way of a change in the...
7.
Bergonzo C, Gallagher D
J Res Natl Inst Stand Technol
. 2022 Dec;
126:126012.
PMID: 36475080
No abstract available.
8.
Chen Y, Toth E, Ruan B, Choi E, Simmerman R, Chen Y, et al.
Commun Biol
. 2021 Mar;
4(1):299.
PMID: 33674772
We describe the design, kinetic properties, and structures of engineered subtilisin proteases that degrade the active form of RAS by cleaving a conserved sequence in switch 2. RAS is a...
9.
Shahid S, Gao M, Gallagher D, Pozharski E, Brinson R, Keck Z, et al.
J Mol Biol
. 2020 Nov;
433(2):166714.
PMID: 33220264
We determined the crystal structure to 1.8 Å resolution of the Fab fragment of an affinity-matured human monoclonal antibody (HC84.26.5D) that recognizes the E2 envelope glycoprotein of hepatitis C virus...
10.
Wu D, Gallagher D, Gowthaman R, Pierce B, Mariuzza R
Nat Commun
. 2020 Jun;
11(1):2908.
PMID: 32518267
Adoptive cell therapy (ACT) with tumor-specific T cells can mediate cancer regression. The main target of tumor-specific T cells are neoantigens arising from mutations in self-proteins. Although the majority of...